Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest

Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Singh A, van der Zwan W, Severi S,

Keywords: biomarker, PRRT, prediction, NETest, PPQ, CgA, personalized medicine,

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,

Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,

#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,

Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,

#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker

Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, van der Zwan W, Singh A, Severi S,

Keywords: Biomarker, carcinoid, PRRT, prediction, therapy, efficacy, stratification,

#1807 Adherence to WHO2010 Guideline for Diagnosis of Neuroendocrine Carcinoma and Prognostic Significance

Introduction: Neuroendocrine carcinoma’s (NEC) are diagnosed by a combination of immunohistochemistry (IHC) and morphology according to the 2010 WHO guidelines.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Zandee W, Van der Zwan J, de Herder W, Van Velthuysen L,

Keywords: neuroendocrine carcinoma, IHC, morphology, diagnosis, prognosis, who 2010 ,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.